BioPharma

AusBiotech CEO Rebekah Cassidy said the investor-focused event will help accelerate the delivery of real-world, home-grown health solutions.

Health Minister Mark Butler has not waited to be reappointed following Saturday's election, confirming a plan to meet with the health department secretary, Blair Comley, yesterday.

Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164.

Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer.

Arovella Therapeutics (ASX:ALA) has entered into an exclusive option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform.

Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy.

Rare Cancers Australia CEO Christine Cockburn said, “This new TGA indication for JEMPERLI is an important step toward greater access for patients, however, a PBS listing is the ideal outcome.

Stakeholders interested in change would support continuity and Mark Butler's reappointment to the health portfolio after the Albanese Government's stunning victory in Saturday's election.

UCB general manager Selina Clifford said, "As our understanding of the genetic mutations underlying Dravet syndrome continues to grow, we remain focused on developing innovative solutions to address the unique challenges of this complex neurological condition."

The pharmaceutical, pharmacy and biotechnology sectors have congratulated the Albanese Government following its reelection at Saturday's election.

What is the balance between building national sovereignty in health and protecting patient safety and community confidence in new technologies? Do we need to be careful? An election brings back memories of 'future' funds past.

Labor and the Coalition share a bipartisan commitment to progressing the Health Technology Assessment Review. However, they also share a decision not to devote any funding to the outcome in their pre-election policy commitments.